Table 3.

Effects on nociceptive pain and itch of various types of VGLUT deletion (Reductions are shown in red, lack of change are shown in black and dashes show pain modalities that have not been assessed; concomitant actions with neuropeptides are shown in purple; & No hyperalgesia according to Draxler et al. 2014 [31]; δ Yes, when concomitant pharmacological blockade of CGRP and/or SP; ⁺ Yes, when concomitant pharmacological blockade of SP and CGRP; £ Yes, when concomitant pharmacological blockade of CGRP; * Yes, when concomitant pharmacological blockade of SP).

Inflammatory Pain
NGF		Capsaicin		Formalin		Carrageenan			CFA
Mech.	Heat	Mech.	Licking Biting	Phase I	Phase II	Mech.	Heat	Cold	Mech.	Heat
Global KO
—	—	—	—	VG1 (+/−) [40]	VG1 (+/−) [40]	—	VG1 (+/−) [40]	—	—	—
—	—	—	—	VG2 (+/−) [40,41]	VG2 (+/−) [40,41]	—	VG2 (+/−) [40,41]	—	—	—
—	—	VG3 (−/−) [30]	—	VG3 (−/−) [30]	VG3 (−/−) [30]	VG3 (−/−) [30,31]	VG3 (−/−) & [30,31]	VG3 (−/−) [31]	—	—
Targeted KO
VG2-DRG [26]	VG2-DRG [26]	—	—	VG2-DRG [26]	VG2-DRG [26]	VG2-DRG [26]	VG2-DRG [26]	—	—	—
—	—	—	VG2-nocicept. [25]	VG2-nocicept. [25]	VG2-nocicept. [25]	VG2-nocicept. [25]	VG2-nocicept. [25]	—	VG2-nocicept. [25]	VG2-nocicept. [25]
VG2-TRPV1 δ [28]	VG2-TRPV1 + [28]	—	—	VG2-TRPV1 £ [6,28,38]	VG2-TRPV1 + [6,28,38]	VG2-TRPV1 + [28]	VG2-TRPV1 + [28]	—	—	—
—	—	—	—	VG2-TH [6]	VG2-TH [6]	—	—	—	—	—
—	VG2- Nav1.8 [27]	—	—	VG2- Nav1.8* [27]	VG2- Nav1.8 * [27]	—	—	—	—	—
—	—	—	VG3-DRG [33]	—	—	VG3-DRG [33]	VG3-DRG [33]	—	VG3-DRG [33]	VG3-DRG [33]

VG1 (+/−), VGLUT1-KO; VG2 (+/−), VGLUT2-KO; VG3 (−/−), VGLUT3-KO; VG2-DRG, VGLUT2-DRG-KO; VG2-nocicept., VGLUT2-nociceptors-KO; VG2-TRPV1, VGLUT2-TRPV1-KO; VG2-TH, VGLUT2-TH-KO; VG2-Nav1.8, VGLUT2-Nav1.8-KO; VG3-DRG, VGLUT3-DRG-KO.